UNITED STATES (VOP TODAY NEWS) — A drug manufacturer from New Haven (Connecticut, USA) and a research center associated with Hamden have conducted a new clinical trial of a drug to slow the development of Alzheimer’s disease.
The American company Biohaven Pharmaceuticals, supported by the Alzheimer’s Disease Cooperative Study at the University of California San Diego, is testing a new drug that could revolutionize the treatment of Alzheimer’s disease, reports the local paper Hartford Courant.
This is troriluzole, specifically designed to help people with Alzheimer’s disease in mild and moderate stages.
According to the company, the drug is based on another drug, riluzole, the first drug approved by the US Food and Drug Administration more than 20 years ago.
Like riluzole, troriluzole has an impact on the substances that nerve cells in the brain use to communicate with each other. This helps in particular to protect against the neurodegeneration of nerve cells. Trililuzole is a prodrug of riluzole, which means it is inactive until it is converted into an active drug during digestion.
Yale University also plans to participate in the study.
This article is written and prepared by our foreign editors writing for VOP from different countries around the world – edited and published by VOP staff in our newsroom.
Support The VOP from as little as $1 – it only takes a minute. Thank you.
We are the Voice of People — the only funding and support we get from people – we are categorically not funded by any political party, any government somewhere or from any grouping that supports certain interests – the only support that makes VOP possible came from you.
VOP Today News — Breaking news source, real-time coverage of the world’s events, life, politics, business, finance, economy, markets, war and conflict zones.
Contact us: firstname.lastname@example.org